emjreviews.com
Cure8 news brief
Ustekinumab Plus Enteral Nutrition Improves Crohn's Outcomes
Medications
Ustekinumab
IL-12/23 inhibitor
Clinical study
Adult patients
Clinicians
Patients On Biologics
Researchers
Why This Matters
The study suggests adding a structured 16-week exclusive enteral nutrition plan to ustekinumab treatment may improve short- and medium-term clinical and endoscopic outcomes for adults with moderate-to-severe Crohn’s disease, a potentially meaningful strategy for patients not achieving optimal control on biologic therapy alone.
Who Should Pay Attention
Adults with moderate-to-severe Crohn’s disease, patients on ustekinumab or considering biologic optimization, gastroenterologists, IBD dietitians, and researchers planning prospective trials of combination therapy.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This report summarizes a retrospective study of 114 adults treated between 2020 and 2024; 56 received ustekinumab plus 16 weeks of EEN and 58 received ustekinumab monotherapy.
At week 16 the combination group had substantially higher reported rates of clinical response (94.6% vs 70.7%), clinical remission (89.3% vs 55.2%), endoscopic response (95.2% vs 58.8%) and mucosal healing (90.5% vs 37.3%). The differences were maintained at week 52, and no severe adverse events were reported in the article.
Interpretation notes Because this was a retrospective, non-randomized cohort study, unmeasured differences between groups and selection biases could affect results. The authors and article suggest these findings support further prospective evaluation of ustekinumab plus EEN rather than establishing definitive benefit.
Discussing feasibility and adherence to 16-week EEN with a treating gastroenterologist or dietitian would be important for anyone considering this approach.
Keep In Mind
This is a retrospective multicentre cohort study (not randomized). The article cites a Sci Rep publication; the cohort design and potential for selection bias mean results are hypothesis-generating and require confirmation in prospective randomized trials. Practical issues such as patient adherence to 16-week EEN and real-world tolerability are not detailed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationemjreviews.com
AuthorsKatrina Thornber
Indexed viaGoogle News
Source typeWeb article
PublishedOct 3, 2026, 1:20 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Ustekinumab combined with upadacitinib promotes endoscopic healing in moderate-to-severe Crohn's disease with anti-TNF-α failure.
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
Real-World Drug Retention and Safety of Ustekinumab in Patients With Inflammatory Bowel Disease in Qatar: A Retrospective Cohort Study.
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...